Further to the announcement dated 10 February 2022 in relation to the Memorandum of Understanding dated 10 February 2022 entered into between Aemulus Corporation Sdn. Bhd. [Company No. 200701039983 (798015-M)] (“ACSB”), a wholly-owned subsidiary of the Company with Tangren Microtelligence Technology (Jiashan) Co., Ltd. (唐人制造（嘉善）有限公司) (Company No. 91330421MA2JDX7R48) (“Tangren”), the Board of Directors (“Board”) of Aemulus wishes to announce that ACSB had on 11 April 2022, entered into a Capital Injection Agreement (the “Agreement”) with Tangren and Tangming Shengshi Technology (Jiashan) Co., Ltd. (唐明盛试科技（嘉善）有限公司) (Company No. 91330421MA2JE6JP6C) (“TMSS”) to increase the registered capital of TMSS (a 40% owned company by ACSB) of Renminbi 25 Million (RMB 25,000,000) and upon the terms and conditions as stipulated in the Agreement (“Capital Injection”).

Further details of the Capital Injection are set out in the attachment.

This announcement is dated 11 April 2022.